Methods and compositions for inhibiting progression to chronic cardiac failure
OwnerJohn E. Fokerinventor
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and formulations for preventing or ameliorating progression to chronic heart failure subsequent to cardiac stress, including as a consequence of myocardial infarction (MI), coronary artery disease, hypertension, cardiomyopathy, myocarditis, valvular regurgitation, severe lung disease, and/or severe anemia of chronic disease, by administration of one or more rate-limiting precursors to the synthesis of ATP. In one embodiment the ATP precursor is a pentose selected from one or more of ribose, D-ribose, ribulose, xylitol, xylulose, and a 5-carbon precursor of ribose.
Claims11
A method of limiting consequences of myocardial stress on cardiac energy levels in a patient diagnosed with myocardial stress and thereby limiting damage to normal cardiac tissue that begins a progression to chronic heart failure comprising providing to the patient a prolonged and continuous administration of a sufficient quantity of at least one ribose moiety that is a rate-limiting precursor to the synthesis of ATP, wherein the administration is initiated by parenteral administration of the at least one ribose moiety for an initial period of about 3 to about 14 days followed by oral administration of the at least one ribose moiety for at least 3 weeks, wherein the prolonged administration at least one ribose moiety is sufficient to normalize and maintain levels of ATP in the stressed myocardium.
A method of limiting effects of stress placed on remaining, often normal, myocardium in patients at risk for developing chronic heart failure (CHF) and thereby limiting a progressive dysfunction that leads to (CHF), comprising:
- identifying a condition placing the patient at risk for development of CHF;
- immediately initiating continuous intravenous administration of a composition including a sufficient quantity of at least one ribose moiety into the patient;
- continuing the intravenous administration for at least three days up to a duration of a hospitalization of the patient;
- continuing administration of the at least one ribose moiety by oral dosage for at least three weeks following the intravenous administration while assessing one or more of LV, systolic, and diastolic function periodically during the oral administration of the at least one ribose moiety, and continuing the oral administration until one or more of the LV, systolic or diastolic function improves in the patient;
- and resuming intravenous administration of the at least one ribose moiety if one or more of the LV, systolic, and diastolic function declines.
Dependencies are inferred from the claim text.